Coherus and AbbVie settle Humira biosimilar dispute after Mark Cuban’s Cost Plus Drugs announcement

Biosimilars player Coherus Biosciences has patched things up with AbbVie after the pharma said Coherus violated its non-exclusive license to commercialize Yusimry, a biosimilar of Humira, a rheumatoid arthritis drug.

On June 6, Coherus received a notice from AbbVie because of Coherus’ announcement on June 1 of its pricing agreement with Mark Cuban Cost Plus Drug Company and its plans to offer Yusimry to Cost Plus Drugs customers beginning in July, according to SEC filings.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Forget ‘Pack-Years’ for Lung Cancer Screening Eligibility, Study Suggests

Dropping pack-years for lung cancer screening eligibility in favor of a simpler 20-year history of smoking could substantially increase the number of cancers detected and

April 2, 2024

Medtronic Expands AI-Driven Partnership with Cosmo Pharmaceuticals

What You Should Know: – Medtronic announced an expanded AI partnership with Cosmo Pharmaceuticals NV, a pharmaceutical company, to further advance AI-powered solutions in the

December 12, 2023

Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?

Patients with cancer want information and advice early in the disease course about how to deal with the financial stressors of their costly care. (Northwestern

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.